AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations ...
Up to 20% of hormone receptor-positive breast cancers don't respond to antiestrogen therapies. A study led by researchers at UT Southwestern, published in the Journal of Clinical Investigation, ...
Oxidative stress happens when free radicals outnumber antioxidants, which can damage fatty tissue, DNA, and proteins throughout your body. Oxidative stress is linked to diseases like diabetes, ...